How suitable their thromboembolism prophylaxis is for patients with chronic auricular fibrillation at 3 primary care centres;Adecuación de la profilaxis tromboembólica en pacientes con fibrilación auricular crónica en 3 centros de atención primaria

Atencion Primaria

Volumn 33, Issue 4, 2004, Pages 188-192

  Romera Fernandez I ^a   De Dios Del Valle, R ^a   Garcia De Francisco A ^a   Gonzalez Rubio Y ^a   Lenza Alonso, C ^a   Salinero Fort, Miguel Angel ^a,b  

^a Instituto Madrileno de la Salud   (Spain)

^b Instituto Madrileno de la Salud   (Spain)

Author keywords

Anticoagulants; Aspirin; Auricular fibrillation

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE;

ADULT; AGED; ARTICLE; DEMOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIMARY MEDICAL CARE; PROPHYLAXIS; RISK FACTOR; SPAIN; THROMBOEMBOLISM;

EID: 2342541107     PISSN: 02126567     EISSN: None     Source Type: Journal    
DOI: 10.1157/13058767     Document Type: Article

References (15)

1. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978;28:973-7.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;22:983-8.
3. Petersen P, Boysen G, Godtfredsen J, Andersen E, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;1: 175-8.
4. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991;84:527-39.
5. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
6. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-55.
7. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12.
8. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomised clinical trials. Arch Intern Med 1994;154:1449-57.
9. Heras M, Fernández A, Gómez JA, Iriarte JA, Lidón RM, Pérez F, et al. Guías de actuación clínica de la Sociedad Española de Cardiología. Recomendaciones para el uso del tratamiento antitrombótico en cardiología. Rev Esp Cardiol 1999;52:801-20.
10. Martín E, Salgado F, Sánchez A, Martos F, González JA, Fuentes T. Valoración del tratamiento antitrombótico en pacientes con fibrilación auricular crónica no valvular. Aten Primaria 1998;22:172-5.
11. Albers GW, Yim JM, Belew KM, Bittar N, Hattemer CR, Phillips BG. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996;156:2311-6.
12. Pétez I, Melbourn A, Kalra L. Use of antithrombotic measures for stroke prevention in atrial fibrillation. Heart 1999;82:570-4.
13. Brotons C, Moral I, Antón JJ, Cobos M, Cucurrull E, Gallego C, et al. Tratamiento preventivo de la fibrilación auricular no reumática: de la eficacia de los ensayos clínicos a la efectividad en la práctica clínica. Aten Primaria 1997;20:367-71.
14. Laupacis A, Alberrs GW, Dalen JE, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 1998;114:579S-89S.
15. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;3:687-91.